The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Our reconstitution solutions are strictly for research use only and intended for in vitro laboratory applications
Semaglutide (Wegovy) is FDA-approved for chronic weight management (with criteria) and has strong clinical trial evidence for meaningful average weight loss when paired with lifestyle support
(109) found that cashew protein hydrolysate inhibited the production of pro-inflammatory cytokines in the brain of rats with arterial occlusion-induced cerebral is chaemia, and by modulating the function of lipid metabolism, its modulation of serum cholesterol, TG, and LDL, and elevation of HDL, greatly improved spatial memory in rats
Trends in Pharmacological Sciences
&srotate=0)
